Histone deacetylase inhibitors as potential therapeutic approaches for chordoma: An immunohistochemical and functional analysis

Journal of Orthopaedic Research

Volumn 31, Issue 12, 2013, Pages 1999-2005

  Scheipl, Susanne ^a   Lohberger, Birgit ^a   Rinner, Beate ^a   Froehlich, Elke Verena ^a   Beham, Alfred ^a   Quehenberger, Franz ^a   Lazáry, Aron ^b   Pal Varga, Peter ^b   Haybaeck, Johannes ^a   Leithner, Andreas ^a   Liegl, Bernadette ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b National Center for Spinal Disorders Buda Health Center   (Hungary)

Author keywords

chordoma; HDAC; HDAC inhibitors; survival; targeted therapies

Indexed keywords

BELINOSTAT; CASPASE 3; CASPASE 7; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; VORINOSTAT;

ADULT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CHORDOMA; CLINICAL ARTICLE; COHORT ANALYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MOLECULARLY TARGETED THERAPY; PRIMARY TUMOR; PRIORITY JOURNAL; SURVIVAL; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR RECURRENCE; WESTERN BLOTTING;

EID: 84886305149     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22447     Document Type: Article

References (23)

1. Casali PG, Stacchiotti S, Sangalli C, et al. 2007. Chordoma. Curr Opin Oncol 19: 367-370.
2. Vujovic S, Henderson S, Presneau N, et al. 2006. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 209: 157-165.
3. Sciubba DM, Chi JH, Rhines LD, et al. 2008. Chordoma of the spinal column. Neurosurg Clin N Am 19: 5-15.
4. Flanagan AM, Yamaguchi T., 2013. Chordoma. In:, Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; p 328-329.
5. Walcott BP, Nahed BV, Mohyeldin A, et al. 2012. Chordoma: current concepts, management, and future directions. Lancet Oncol 13: e69-e76.
6. Hug EB., 2001. Review of skull base chordomas: prognostic factors and long-term results of proton-beam radiotherapy. Neurosurg Focus 10: E11.
7. Kim HJ, Bae SC., 2011. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 3: 166-179.
8. Lane AA, Chabner BA., 2009. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-5468.
9. Ma X, Ezzeldin HH, Diasio RB., 2009. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69: 1911-1934.
10. Marks PA, Xu WS., 2009. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107: 600-608.
11. Jenuwein T, Allis CD., 2001. Translating the histone code. Science 293: 1074-1080.
12. Scheipl S, Froehlich EV, Leithner A, et al. 2012. Does insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study. Histopathology 60: 999-1003.
13. Scheil S, Bruderlein S, Liehr T, et al. 2001. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 32: 203-211.
14. Rinner B, Froehlich EV, Buerger K, et al. 2012. Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1. Int J Oncol 40: 443-451.
15. Froehlich EV, Scheipl S, Lazary A, et al. 2012. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis. Spine (Phila Pa 1976) 37: E757-E767.
16. Duan Z, Choy E, Nielsen GP, et al. 2010. Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression. J Orthop Res 28: 746-752.
17. Boyault C, Sadoul K, Pabion M, et al. 2007. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 26: 5468-5476.
18. Matthias P, Yoshida M, Khochbin S., 2008. HDAC6 a new cellular stress surveillance factor. Cell Cycle 7: 7-10.
19. Kwon S, Zhang Y, Matthias P., 2007. The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress response. Genes Dev 21: 3381-3394.
20. Kawaguchi Y, Kovacs JJ, McLaurin A, et al. 2003. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115: 727-738.
21. Khan N, Jeffers M, Kumar S, et al. 2008. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409: 581-589.
22. Hrzenjak A, Moinfar F, Kremser ML, et al. 2010. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer 9: 49.
23. Dejligbjerg M, Grauslund M, Litman T, et al. 2008. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells. Mol Cancer 7: 70.